HEB News Breaks Hemispherx files NDA in Argentina for Ampligen to treat CFS
July 18, 2012
08:10 EDT HEB theflyonthewall.com: Hemispherx files NDA in Argentina for Ampligen to treat CFS
Hemispherx Biopharma announced that it has submitted a new drug application, or NDA, to ANMAT, or Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica, the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, under the ANMAT's Orphan Drug regulations. Ampligen is an experimental drug currently undergoing clinical development for the treatment of Chronic Fatigue Syndrome, or CFS, in the U.S. :theflyonthewall.com